How Red Pigmentation in Foods Helps Fight Lung Cancer

For those of you smokers, we aren’t saying you shouldn’t quit!  However, to help counteract some of the harmful effects of nicotine check out this article for the healing benefits of red pigmentation in certain foods.

https://m.medicalxpress.com/news/2017-01-red-pigment-peppers-oranges-linked.html

 

Researchers find BCX—red pigment abundant in sweet red peppers, paprika, winter and butternut squash, oranges, and tangerines, among other foods—appears to counteract nicotine’s ability to accelerate the growth of lung tumors. Credit: Ingimage

Great News Coffee Lovers!!

#Coffee is addictive but this just maybe one of the few good “drugs” to be addicted to, in moderation!  Did you know that drinking one cup of coffee a day can help lower your risk of diabetes, liver cancer, melanoma, and multiple sclerosis?  It can also help enhance memory, boost your mood, and this one you’ll never guess decrease tooth decay!!  So for all of my fellow coffee addicts out there drink up guilt-free!
#kimbo Kimbo

coffee.jpg

 

http://www.itechpost.com/articles/76352/20170120/why-every-guy-should-drink-coffee-discover-coffees-health-benefits.htm

Treating a cancer patient for a second time

In order to determine whether a growth represents relapse of a previously diagnosed cancer or is a newly developed, separate tumor, doctors obtain a tissue sample from the patient and have it examined by a pathologist.
#prevention #cancer #tumor

ccs-kidney-cf363-13-left

A tumor from a young boy’s kidney (a normal kidney tubule is visible top right).

http://blog.dana-farber.org/insight/2017/01/when-cancer-occurs-in-someone-who-has-already-been-treated-how-do-doctors-determine-whether-its-a-new-tumor-or-the-spread-of-the-earlier-tumor/

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Finding the ideal combination of targeted, hormonal and chemotherapeutic agents to treat HER2-negative metastatic breast cancer has been challenging researchers for decades. In tumors which lack expression of the human epidermal growth factor receptor 2 (HER2-), the use of regimens based on the administration of paclitaxel, a taxane, and bevacizumab, a humanized monoclonal antibody directed against VEGF-A, eventually integrated by maintenance therapy with bevacizumab and/or endocrine therapy may represent a valuable therapeutic option. In other words, an initial round of targeted chemotherapy to rapidly halt cancer progression, followed by maintenance therapy to prevent further metastases. The specific drug regimen analyzed in a recent study resulted in better control of disease progression and a higher overall survival rate.

The study, “A Real-World Multicentre Retrospective Observational Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line Treatment for HER2-Negative Metastatic Breast Cancer,” was recently published in the Journal of Cell Physiology an international, peer-reviewed journal focused on cancer-related issues.

Researchers identified 314 patients diagnosed with HER2-negative metastatic breast cancer at 12 Italian cancer centres. From that group, they identified a subgroup of about 180 hormone-receptor positive patients to administer maintenance endocrine therapy following paclitaxel discontinuation, which was eventually combined with bevacizumab maintenance therapy.

“Notwithstanding the overall improvement in the available therapeutic options, metastatic breast cancer is still considered incurable,” says Dr. Maddalena Barba, researcher at the Regina Elena National Cancer Institute of Rome, Central Italy, “with particularly low survival rates in some patient subgroups for whom novel treatment combinations and potential therapeutic targets are urgently needed.”

The authors belong to a multidisciplinary Italian-American team, which has long collaborated with Prof. Antonio Giordano, Director of the Sbarro Institute for Cancer Research, Temple University Philadelphia, USA

“In this study, we observed evidence of the efficacy of first-line paclitaxel-bevacizumab in metastatic HER2 negative breast cancer patients. In addition, both bevacizumab and endocrine maintenance therapy significantly improved slowing disease progression and the overall survival rate, compared to cases with no maintenance therapies,” says Dr Vici, clinical researcher at the division of Medical Oncology 2 of the Regina Elena National Cancer Institute.

“When addressing metastatic breast cancer, pathologists and oncologists work jointly to identify single therapeutic approaches to be used within a wider therapeutic strategy,” says Prof. Antonio Giordano, a scientist with widely recognized expertise in breast cancer with a specific focus on translational research. “Each step of the decision making process is driven by specific disease features, such as the lack or presence of therapeutic important targets, which may be exemplified by HER2 and hormone receptors, along with our patients specific needs. In addition, data collected from real world populations, likewise those commonly involved in our research pipeline on breast cancer, are closer to the routine clinical practice and patient needs compared to the evidence from randomized clinical trials, whose participants are generally highly selected,” Prof. Giordano concluded.

News-Medical Release        PubMed Abstract

International Award Giovan Giacomo Giordano NIAF-Ethics and Creativity in medical research – Saturday, 9 A.M October 15th at the Marriot Wardman Park Hotel in Washington, D.C.

official-niaf-2016-flyerWomen Leaders in advanced Cancer Research

The Sbarro Health Research Organization (SHRO), in collaboration with Temple University’s College of Science and Technology, the National Italian American Foundation (NIAF), and the Giovan Giacomo Giordano Foundation will host the medical conference “Women Leaders in Advanced Cancer Research” 9 A.M on Saturday, October 15th at the Marriot Wardman Park Hotel in Washington, D.C.

The conference will feature an introduction on “Women Leaders in Advanced Cancer Research” presented by SHRO’s President Antonio Giordano who is also director of Temple’s Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology.  Temple and CST are leaders in biotech research and development, and recently launched masters programs in both bioinnovation and biotechnology.

Guest speakers include Maria Catherine Pietanza, Global Director of Scientific Affairs for Oncology Center Merck Research Laboratories, Francesca Pentimalli, Adjunct Faculty at Temple University, and Michele Masucci, Vice President for Research at Temple University.  Dr. Pietanza will address “Activating the Immune System Against Cancer: where are we?”. Dr. Pentimalli will discuss “Cancer and the Environment: What did we learn from the Mesothelioma Case?” and Dr. Masucci will report on “Strategies for meeting the needs of the 21st Century STEM Workforce in Academia”.  A special recognition will be given to Dr. Pentimalli for her work in the field of mesothelioma.

The conference will culminate in the presentation of the 2016 Giovan Giacomo Giordano NIAF Lifetime Achievement Award for Ethics and Creativity in Medical Research by Mrs. Dolores Del Raso and Dr. Giacomina Massaro to Dr. Pietanza and Dr. Masucci.  This award was established six year ago in honor of Dr. Giordano’s father, the late Professor Giovan Giacomo Giordano, renowned pathologist and former chair of the Department of Pathology, National Cancer Institute of Naples and professor at the Second University of Naples, who dedicated more than sixty years of his life to the study of cancer and the role of environmental factors in the onset of this disease.  Professor Giovan Giacomo Giordano was also a major advocate against corruption in the Italian medical community and driving force for the establishment of medical ethical standards among his colleagues.

An exclusive preview of the Carlo Fumo-directed documentary “Land of Poison”, on the ongoing environmental and health problems facing the Campania area of Italy, will also be shown.

The Complex Crosstalk Between Obesity & Breast Cancer

Figure-1.pngA new study published in the Journal of Cellular Physiology  (abstract) describes how inflammation that characterizes fatty tissue is one of the main microenvironment actors responsible for promoting cancer. The authors also describe the involvement of steroid hormones and others factors produced by adipose tissue in breast cancer development.

The study, “Multifaceted breast cancer: the molecular connection with obesity,” appeared in the July 1, 2016 edition of the international, per-reviewed journal focused on cancer-related issues. The authors belong to a multidisciplinary Italian-American-Tunisian team with a long and productive history of collaboration with Prof. Antonio Giordano, Director of the Sbarro Institute for Cancer Research, Temple University of Philadelphia, Pennsylvania, USA.

A novel approach was developed to analyze cell culture systems by professor Pietro Formisano from the University of Naples “Federico II” (NA, Italy), in order to study interactions between adipose tissue and tumors, and the molecular mechanism of insulin action. The contribution of professor Angelina Di Carlo, University of Rome “La Sapienza” (Rome, Italy), was to underline the role of matrix metalloproteinases in obesity-related mechanisms of breast carcinogenesis. The work by Professor Soumaya Kouidhi, of Manouba Thabet University (Aryanah,Tunisia), suggests that the small circulating RNA could be important in the diagnosis and prognosis of breast cancer. Finally, professor Marina Di Domenico from the Second University of Naples (Italy) and PI of IRCCS “La salute della donna” of “Malzoni Clinic ” (AV, Italy), describes the “non genomic” actions of estrogen receptors in relation to breast cancer, with particular reference to the main roles of p85 / PI3K, in differentiation and cell migration.

This publication, resulting from an excellent exchange of worldwide knowledge, represents an important contribution in the studies of molecular mechanisms regulating breast cancer pathogenesis.

See Science Daily release.

Dr Antonio Giordano visits Medical Research institutions In Santiago Chile

Dr. Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, was invited as an expert in scientific research to evaluate the Advanced Centers for Chronic Disease in Chile, one of the most important among centers of excellence in scientific research, established at the Catholic University in Chile and the University of Chile.  The program is funded by CONICYT, a Chilean government agency that is part of the Ministry of Education and is responsible for coordinating, promoting and aiding scientific research in the country. The name is an acronym for Comisión Nacional de Investigación Científica y Tecnológica, meaning “National Commission of Scientific Research and Technology”.  During his visit, Dr. Giordano was invited by  the Italian Ambassador in Santiago, the Honorable Marco Ricci, to meet several leaders from the Italian community in Chile.

schermata20160525alle14-29-47

Dr Antonio Giordano and Ambassador Marco Ricci in Santiago, Chile

Original post o shrodiary.ning.com